TY - JOUR
T1 - Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the fame trials
AU - Parrish, Richard K.
AU - Campochiaro, Peter A.
AU - Pearson, P. Andrew
AU - Green, Ken
AU - Traverso, Carlo E.
PY - 2016/5
Y1 - 2016/5
N2 - BACKGROUND AND OBJECTIVE: To compare elevated intraocular pressure (IOP) management and outcomes among patients with diabetic macular edema who received fluocinolone acetonide (FAc) implants versus sham-control treatment and explore the prior ocular steroid exposure impact on IOP outcomes. PATIENTS AND METHODS: Best-corrected visual acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study charts or electronic VA testers. Goldmann applanation tonometry was used to measure IOP. RESULTS: Elevated IOP was more common in FAcversus sham control-treated patients. Medication, and less often trabeculoplasty or surgery, was used to lower IOP without affecting VA outcomes. No patient treated with 0.2 ?g/day FAc who received prior ocular steroid required IOP-lowering surgery. CONCLUSION: Elevated IOP may occur following FAc implant receipt; however, in the present study, it was manageable and did not impact vision outcomes. Patients previously treated with ocular steroid did not require IOP-lowering surgery following 0.2 ?g/day FAc implant administration.
AB - BACKGROUND AND OBJECTIVE: To compare elevated intraocular pressure (IOP) management and outcomes among patients with diabetic macular edema who received fluocinolone acetonide (FAc) implants versus sham-control treatment and explore the prior ocular steroid exposure impact on IOP outcomes. PATIENTS AND METHODS: Best-corrected visual acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study charts or electronic VA testers. Goldmann applanation tonometry was used to measure IOP. RESULTS: Elevated IOP was more common in FAcversus sham control-treated patients. Medication, and less often trabeculoplasty or surgery, was used to lower IOP without affecting VA outcomes. No patient treated with 0.2 ?g/day FAc who received prior ocular steroid required IOP-lowering surgery. CONCLUSION: Elevated IOP may occur following FAc implant receipt; however, in the present study, it was manageable and did not impact vision outcomes. Patients previously treated with ocular steroid did not require IOP-lowering surgery following 0.2 ?g/day FAc implant administration.
UR - http://www.scopus.com/inward/record.url?scp=84983439216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983439216&partnerID=8YFLogxK
U2 - 10.3928/23258160-20160419-05
DO - 10.3928/23258160-20160419-05
M3 - Article
C2 - 27183546
AN - SCOPUS:84983439216
SN - 2325-8160
VL - 47
SP - 426
EP - 435
JO - Ophthalmic Surgery Lasers and Imaging Retina
JF - Ophthalmic Surgery Lasers and Imaging Retina
IS - 5
ER -